Detailed molecular epidemiologic characterization of HIV-1 infection in Bulgaria reveals broad diversity and evolving phylodynamics

PLoS One. 2013;8(3):e59666. doi: 10.1371/journal.pone.0059666. Epub 2013 Mar 19.

Abstract

Limited information is available to describe the molecular epidemiology of HIV-1 in Bulgaria. To better understand the genetic diversity and the epidemiologic dynamics of HIV-1 we analyzed 125 new polymerase (pol) sequences from Bulgarians diagnosed through 2009 and 77 pol sequences available from our previous study from persons infected prior to 2007. Epidemiologic and demographic information was obtained from each participant and phylogenetic analysis was used to infer HIV-1 evolutionary histories. 120 (59.5%) persons were infected with one of five different HIV-1 subtypes (A1, B, C, F1 and H) and 63 (31.2%) persons were infected with one of six different circulating recombinant forms (CRFs; 01_AE, 02_AG, 04_cpx, 05_DF, 14_BG, and 36_cpx). We also for the first time identified infection with two different clusters of unique A-like and F-like sub-subtype variants in 12 persons (5.9%) and seven unique recombinant forms (3.5%), including a novel J/C recombinant. While subtype B was the major genotype identified and was more prevalent in MSM and increased between 2000-2005, most non-B subtypes were present in persons ≥45 years old. CRF01_AE was the most common non-B subtype and was higher in women and IDUs relative to other risk groups combined. Our results show that HIV-1 infection in Bulgaria reflects the shifting distribution of genotypes coincident with the changing epidemiology of the HIV-1 epidemic among different risk groups. Our data support increased public health interventions targeting IDUs and MSM. Furthermore, the substantial and increasing HIV-1 genetic heterogeneity, combined with fluctuating infection dynamics, highlights the importance of sustained and expanded surveillance to prevent and control HIV-1 infection in Bulgaria.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Base Sequence
  • Bayes Theorem
  • Bulgaria / epidemiology
  • Computational Biology
  • Evolution, Molecular*
  • Female
  • Genetic Variation*
  • HIV Infections / epidemiology*
  • HIV-1 / genetics*
  • Humans
  • Likelihood Functions
  • Male
  • Models, Genetic
  • Molecular Epidemiology
  • Molecular Sequence Data
  • Phylogeny*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Sequence Analysis, DNA
  • Species Specificity
  • pol Gene Products, Human Immunodeficiency Virus / genetics

Substances

  • pol Gene Products, Human Immunodeficiency Virus

Associated data

  • GENBANK/JQ259060
  • GENBANK/JQ259061
  • GENBANK/JQ259062
  • GENBANK/JQ259063
  • GENBANK/JQ259064
  • GENBANK/JQ259065
  • GENBANK/JQ259066
  • GENBANK/JQ259067
  • GENBANK/JQ259068
  • GENBANK/JQ259069
  • GENBANK/JQ259070
  • GENBANK/JQ259071
  • GENBANK/JQ259072
  • GENBANK/JQ259073
  • GENBANK/JQ259074
  • GENBANK/JQ259075
  • GENBANK/JQ259076
  • GENBANK/JQ259077
  • GENBANK/JQ259078
  • GENBANK/JQ259079
  • GENBANK/JQ259080
  • GENBANK/JQ259081
  • GENBANK/JQ259082
  • GENBANK/JQ259083
  • GENBANK/JQ259084
  • GENBANK/JQ259085
  • GENBANK/JQ259086
  • GENBANK/JQ259087
  • GENBANK/JQ259088
  • GENBANK/JQ259089
  • GENBANK/JQ259090
  • GENBANK/JQ259091
  • GENBANK/JQ259092
  • GENBANK/JQ259093
  • GENBANK/JQ259094
  • GENBANK/JQ259095
  • GENBANK/JQ259096
  • GENBANK/JQ259097
  • GENBANK/JQ259098
  • GENBANK/JQ259099
  • GENBANK/JQ259100
  • GENBANK/JQ259101
  • GENBANK/JQ259102
  • GENBANK/JQ259103
  • GENBANK/JQ259104
  • GENBANK/JQ259105
  • GENBANK/JQ259106
  • GENBANK/JQ259107
  • GENBANK/JQ259108
  • GENBANK/JQ259109
  • GENBANK/JQ259110
  • GENBANK/JQ259111
  • GENBANK/JQ259112
  • GENBANK/JQ259113
  • GENBANK/JQ259114
  • GENBANK/JQ259115
  • GENBANK/JQ259116
  • GENBANK/JQ259117
  • GENBANK/JQ259118
  • GENBANK/JQ259119
  • GENBANK/JQ259120
  • GENBANK/JQ259121
  • GENBANK/JQ259122
  • GENBANK/JQ259123
  • GENBANK/JQ259124
  • GENBANK/JQ259125
  • GENBANK/JQ259126
  • GENBANK/JQ259127
  • GENBANK/JQ259128
  • GENBANK/JQ259129
  • GENBANK/JQ259130
  • GENBANK/JQ259131
  • GENBANK/JQ259132
  • GENBANK/JQ259133
  • GENBANK/JQ259134
  • GENBANK/JQ259135
  • GENBANK/JQ259136
  • GENBANK/JQ259137
  • GENBANK/JQ259138
  • GENBANK/JQ259139
  • GENBANK/JQ259140
  • GENBANK/JQ259141
  • GENBANK/JQ259142
  • GENBANK/JQ259143
  • GENBANK/JQ259144
  • GENBANK/JQ259145
  • GENBANK/JQ259146
  • GENBANK/JQ259147
  • GENBANK/JQ259148
  • GENBANK/JQ259149
  • GENBANK/JQ259150
  • GENBANK/JQ259151
  • GENBANK/JQ259152
  • GENBANK/JQ259153
  • GENBANK/JQ259154
  • GENBANK/JQ259155
  • GENBANK/JQ259156
  • GENBANK/JQ259157
  • GENBANK/JQ259158
  • GENBANK/JQ259159
  • GENBANK/JQ259160
  • GENBANK/JQ259161
  • GENBANK/JQ259162
  • GENBANK/JQ259163
  • GENBANK/JQ259164
  • GENBANK/JQ259165
  • GENBANK/JQ259166
  • GENBANK/JQ259167
  • GENBANK/JQ259168
  • GENBANK/JQ259169
  • GENBANK/JQ259170
  • GENBANK/JQ259171
  • GENBANK/JQ259172
  • GENBANK/JQ259173
  • GENBANK/JQ259174
  • GENBANK/JQ259175
  • GENBANK/JQ259176
  • GENBANK/JQ259177
  • GENBANK/JQ259178
  • GENBANK/JQ259179
  • GENBANK/JQ259180
  • GENBANK/JQ259181
  • GENBANK/JQ259182
  • GENBANK/JQ259183
  • GENBANK/JQ259184

Grants and funding

This study was funded in part by the Bulgarian Ministry of Health Directorate “Management of Specialized Donor-funded Programs” and by the European Commission sixth framework supported programs EuropeHIVResistance, grant LSHPCT-2006-518211. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.